Latest news for GlobalData (OTC:GLDAF) Stock

GlobalData PLC is a UK-based data analyzing and publishing company. The firm conducts industry analysis and research reports and also provides forecasts to help its clients make informed decisions. The company has spread across the Asia Pacific, EMEA, Latin and North America serving clients from the consumer, information communications technology, and healthcare markets. The Group operates within a single segment, data, analytics, and insights.

GlobalData PLC

Thanksgiving, a time for gratitude and familial gatherings, often brings its own set of stresses and strains. Back in 2015, <a href="http://benzinga.com/cannabis">cannabis</a> was harder to access due to more restrictive laws. That year, Maureen Meehan wrote an <a href="https://hightimes.com/health/science/5-scientific-benefits-to-smoking-pot-on-thanksgiving">article</a> for High Times spotlighting how cannabis could take the edge off holiday chaos.
Nearly a decade later, with cannabis now mainstream in much of the U.S., we're revisiting and expanding her list to explore how this versatile plant can scientifically improve your Thanksgiving experience.
Here are 10 science-backed reasons why cannabis might just be the ultimate holiday companion:
<h3 class="wp-block-heading">1. Stimulates Appetite And Enhances Taste</h3>
Cannabis is known to trigger the munchies. A 2014 <a href="https://www.smithsonianmag.com/science-nature/scientific-explanation-how-marijuana-causes-munchies-180949660/?utm_source=chatgpt.com">study</a> found that THC, the primary psychoactive component, enhances the sense of smell and taste, leading to increased appetite—perfect for enjoying the Thanksgiving feast.
<h3 class="wp-block-heading">2. Improves Social Bonding</h3>
The &#8220;love hormone&#8221; oxytocin is associated with social bonding. A <a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC4653148/">study</a> from the University of California Irvine discovered that cannabinoids interact with the same brain areas as oxytocin, potentially improving interpersonal connections during family gatherings.
<h3 class="wp-block-heading">3. Aids Digestive Health</h3>
Cannabis has protective effects on the stomach lining. A 2013 <a href="https://www.sciencedirect.com/science/article/abs/pii/S0163782711000026?via%3Dihub">study</a> published in the Journal of Physiology and Pharmacology indicated that cannabinoids could help manage digestive disorders, reducing discomfort after a heavy meal.
<ul>
<li>Get Benzinga&#8217;s exclusive analysis and the top news about the cannabis industry and markets daily in your inbox for free. Subscribe to our newsletter <a href="https://newsletteremail.benzinga.com/subscribe">here</a>. If you&#8217;re serious about the business, you can&#8217;t afford to miss out.</li>
</ul>
<h3 class="wp-block-heading">4. Reduces Anxiety</h3>
Feeling stressed about family interactions? <a href="https://www.sciencedaily.com/releases/2014/03/140306142803.htm">Research</a> from Vanderbilt University suggests that boosting the body&#8217;s natural cannabinoid levels with cannabis can alleviate anxiety, helping you stay calm during tense moments.
<h3 class="wp-block-heading">5. Safer Alternative To Alcohol</h3>
Cannabis is considered <a href="https://www.benzinga.com/markets/cannabis/23/11/35943879/cannabis-vs-alcohol-which-is-preferable-for-better-sleep-among-those-suffering-from-anxiety">safer than alcohol</a>, especially <a href="https://www.benzinga.com/markets/cannabis/24/02/36969871/is-weed-worse-than-alcohol-for-driving-new-study-challenges-common-dui-assumptions">when it comes to driving</a> and avoiding hangovers. Opting for cannabis over that extra glass of wine might make for a clearer morning after.
Read Also: <a href="https://www.benzinga.com/government/regulations/24/11/42173811/hemp-and-thanksgiving-from-the-mayflower-to-independence-the-crop-that-helped-build-a-nation">Hemp And Thanksgiving: From The Mayflower To Independence, The Crop That Helped Build A Nation</a>
<h3 class="wp-block-heading">6. Provides Pain Relief</h3>
A large-scale Canadian study found that <a href="https://www.benzinga.com/markets/cannabis/24/01/36578723/huge-study-reveals-cannabis-provides-similar-pain-relief-benefits-as-opioids-without-negative-co">cannabis offers similar pain relief benefits as opioids</a> but without the negative consequences like respiratory depression. This could be beneficial for managing chronic pain during the holidays.
<h3 class="wp-block-heading">7. Boosts Mental Capacity</h3>
Research from the University of Bonn suggests that low doses of THC may reverse brain aging and <a href="https://www.benzinga.com/markets/cannabis/24/08/40536603/can-thc-turn-back-the-clock-cannabis-reverses-brain-aging-boosts-mental-capacity-new-study-sugge">enhance cognitive functions</a>. This could keep conversations lively and engaging at the dinner table.
<h3 class="wp-block-heading">8. Reduces Inflammation</h3>
A study co-published by Gb Sciences (OTC:<a class="ticker" href="https://www.benzinga.com/stock/GBLX#OTC">GBLX</a>) demonstrated that certain cannabinoids and terpenes in cannabis <a href="https://www.benzinga.com/markets/cannabis/22/11/29510362/cannabis-terpenes-reduce-inflammation-says-gb-sciences-study">have anti-inflammatory properties</a>. This might help alleviate minor aches or discomfort from long hours of preparation and socializing.
<h3 class="wp-block-heading">9. Improves Sleep Quality</h3>
Struggling with sleep after the festivities? Recent research from Washington State University found that over 80% of cannabis users replaced over-the-counter or prescription sleep aids with cannabis. Strains high in THC, CBD and myrcene <a href="https://www.benzinga.com/markets/cannabis/23/11/35952698/cannabis-users-ditch-conventional-sleep-aids-for-natural-remedy-new-study-finds">can improve sleep duration</a>, helping you wake up refreshed.
<h3 class="wp-block-heading">10. Elevates Mood Without Affecting Creativity</h3>
While cannabis may not boost creativity, a study from the University of Washington found that <a href="https://www.benzinga.com/markets/cannabis/23/04/31948043/cannabis-does-not-make-you-more-creative-concludes-study-more-cheerful-yes">it can improve mood</a>. A happier mindset can contribute to a more enjoyable holiday experience for everyone involved.
As always, <a href="https://www.benzinga.com/news/legal/24/11/42177984/joe-biden-how-about-pardoning-non-violent-cannabis-prisoners-along-with-those-thanksgiving-turkeys">consume responsibly</a> and be mindful of local laws and regulations. Enjoy a happier, healthier and more connected celebration.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/cannabis/24/09/41054426/top-10-cannabis-harm-reduction-tips-for-safer-use-and-better-experiences">Top 10 Cannabis Harm Reduction Tips For Safer Use And Better Experiences</a></li>
</ul>
Image generated with AI tools.

Cannabis

Health Care

GBLX

Cannabis On Thanksgiving: 10 Science-Backed Benefits For A Happier Holiday

JPMorgan analysts are offering a fresh perspective on managing market volatility: betting on <a href="https://www.benzinga.com/topic/vix">the VIX (volatility index)</a> while trimming downside hedges on the SPDR S&amp;P 500 ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>). Here's what they're suggesting and why.
<h2 class="wp-block-heading">Elevated SPY Skew Reflects Investor Caution</h2>
The S&amp;P 500&#8217;s options market has been buzzing as investors brace for uncertainties like recession fears and conflicting signals from central banks, particularly the Federal Reserve and the Bank of Japan. This demand for protection has made SPY put options pricey, with their skew—a measure of demand for downside protection—hitting elevated levels.
Read Also: <a href="https://www.benzinga.com/24/11/42210528/us-stock-futures-signal-a-muted-open-smallcaps-may-advance-analyst-flags-cross-asset-volatility">Major US Stock Futures Slide, Small-Caps Buck Trend: Market Strategist Flags This As The &#8216;Stronger Times Of The Year For Stocks&#8217;</a>
<h2 class="wp-block-heading">VIX Calls: A Cheaper Hedge Against Market Swings</h2>
Meanwhile, the VIX, often called the "fear gauge," has seen its call options gain popularity as investors see their relative value.
Compared to the expensive SPY puts, VIX calls appear cheaper while offering a way to hedge against market swings.
<h2 class="wp-block-heading">JPMorgan's Strategy: Balance Risk &amp; Cost</h2>
JPMorgan analysts argue this divergence presents a golden opportunity. Their trade idea? 
Go "long" on VIX calls—essentially betting on market volatility increasing—while going "short" on SPY puts to take advantage of their inflated pricing. 
This approach balances the premium costs and offers a smart hedge if the markets turn turbulent.
<h2 class="wp-block-heading">Why It Matters</h2>
In simple terms, the analysts believe this strategy lets investors stay prepared for market shocks without overpaying for protection. The setup is designed to be premium-neutral, meaning no additional upfront costs, while targeting a sweet spot in relative value.
As market dynamics evolve, this trade might appeal to those who want to play the volatility game smartly. But as with any market bet, timing and risk tolerance will be key.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/24/11/42210528/us-stock-futures-signal-a-muted-open-smallcaps-may-advance-analyst-flags-cross-asset-volatility">Dollar, Treasury Yields, Stocks Fall In Tandem After October Inflation Uptick</a></li>
</ul>
Image created using artificial intelligence via Midjourney.

Analyst Color

Long Ideas

Broad U.S. Equity ETFs

Short Ideas

Analyst Ratings

Trading Ideas

ETFs

JPMorgan's Volatility Play: Long VIX Calls, Short SPY Puts

News

Becton, Dickinson and Company 10-K Risk Factors Highlight Intensified Global Economic Pressures, Stricter Regulations, Evolving Cybersecurity Threats, Climate Change Impacts, Geopolitical Risks, And Expanded Focus On Competition, Healthcare Costs, And Public Health Crises

In the current session, the stock is trading at $296.37, after a 0.01% spike. Over the past month, McDonald's Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MCD#NYSE">MCD</a>) stock increased by 1.66%, and in the past year, by 5.16%. With performance like this, long-term shareholders are optimistic but others are more likely to look into the price-to-earnings ratio to see if the stock might be overvalued.

<img src="https://www.benzinga.com/files/images/story/2024/1732735820_0.png" alt="Past Year Chart" />

<h3>A Look at McDonald's P/E Relative to Its Competitors</h3>
The P/E ratio measures the current share price to the company's EPS. It is used by long-term investors to analyze the company's current performance against it's past earnings, historical data and aggregate market data for the industry or the indices, such as S&amp;P 500. A higher P/E indicates that investors expect the company to perform better in the future, and the stock is probably overvalued, but not necessarily. It also could indicate that investors are willing to pay a higher share price currently, because they expect the company to perform better in the upcoming quarters. This leads investors to also remain optimistic about rising dividends in the future. 
McDonald's has a lower P/E than the aggregate P/E of 88.44 of the Hotels, Restaurants &amp; Leisure industry. Ideally, one might believe that the stock might perform worse than its peers, but it's also probable that the stock is undervalued. 

<img src="https://www.benzinga.com/files/images/story/2024/1732735820_1.png" alt="Guage" />

In conclusion, the price-to-earnings ratio is a useful metric for analyzing a company's market performance, but it has its limitations. While a lower P/E can indicate that a company is undervalued, it can also suggest that shareholders do not expect future growth. Additionally, the P/E ratio should not be used in isolation, as other factors such as industry trends and business cycles can also impact a company's stock price. Therefore, investors should use the P/E ratio in conjunction with other financial metrics and qualitative analysis to make informed investment decisions.

Intraday Update

Markets

Price Over Earnings Overview: McDonald's

California-based cannabis operator Gold Flora Corp. (OTC:<a class="ticker" href="https://www.benzinga.com/stock/GRAM#OTC">GRAM</a>) is on the brink of receivership (a legal process in which a court appoints an independent party to manage a company's assets and operations, often as a last-ditch effort to recover debts or restructure the business) as it struggles with significant financial challenges. As MJBiz Daily <a href="https://mjbizdaily.com/marijuana-operator-gold-flora-facing-receivership-amid-financial-challenges/">reported</a>, the financial recovery firm Global Assets Liens &amp; Foreclosure has <a href="https://mjbizdaily.com/wp-content/uploads/2024/11/Gold-Flora-Receivership-Press-Release.pdf">filed an ex parte application</a> for receivership in Santa Barbara Superior Court, citing more than $236,725 in unpaid invoices. The hearing is scheduled for November 27.
<h3 class="wp-block-heading">Receivership Specialist Tapped</h3>
Global Assets has requested Kevin Singer of Receivership Specialists, known for handling cannabis industry cases involving Herbl, High Times and StateHouse Holdings (OTCPK: STHZF), to serve as receiver for Gold Flora. Currently operating under a limited receivership in Delaware, Gold Flora has reported losses exceeding $37 million.
<h3 class="wp-block-heading">Liquidity Crisis And Cost-Cutting Measures</h3>
Recent filings reveal that Gold Flora is grappling with severe liquidity issues. A proxy statement highlighted a 1-for-50 reverse stock split and plans for substantial share issuance as part of its survival strategy. The company is also implementing cost-cutting measures, including a 10% payroll reduction, according to chief financial officer Marshall Minor during a November 14 earnings call.
<h3 class="wp-block-heading">Expansion Amid Financial Struggles</h3>
Despite its financial instability, Gold Flora CEO Laurie Holcomb announced plans to expand the company's portfolio, emphasizing the launch of its new Gramlin cannabis products. This move comes as the company works to stabilize operations after its 2023 merger with TPCO Holdings, also known as The Parent Co.
The merger, an all-stock deal, resulted in the formation of a new parent company, operating as Gold Flora Corp. It provided access to a $5 million line of credit from The Parent Co. at a 10% annual interest rate secured by Gold Flora's assets. The deal was projected to streamline operations and deliver annual savings of $20 million to $25 million, though the company's current financial state suggests those benefits have yet to materialize.
<h3 class="wp-block-heading">The Road Ahead</h3>
Gold Flora's financial troubles highlight ongoing challenges for cannabis operators navigating a competitive and highly regulated industry. The upcoming hearing could determine the company's future as it attempts to balance cost-cutting with expansion plans.
Gold Flora shares traded up 4.91% at $0.043 per share at the time of this publication.
Cover image made with AI

Psychedelics

Legal

Media

GRAM

GRAMF

STEEL AND TUBE HLDGS LTD by Steel and Tube Holdings Ltd

STHZF

Gold Flora Faces Receivership Proceedings As Financial Struggles Deepen

Alibaba Group Holding Ltd (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BABA#NYSE">BABA</a>) (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BABAF#NYSE">BABAF</a>) and PDD Holdings Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PDD#NASDAQ">PDD</a>) were once the shining stars of China's e-commerce universe, but recent performance metrics suggest they're caught <a href="https://www.benzinga.com/topic/e-commerce">in a gravitational pull downward</a>.
Let's dive into the tale of two stocks that seem to be competing for the title of &#8216;most bearish trend.&#8217;
<h2 class="wp-block-heading">Alibaba: The Resilient Underdog?</h2>
Alibaba's stock, at $86.73, has weathered a mix of optimism and anxiety. It's up 12.12% over the past year, but the last month saw a sharp 13.01% decline. 
<figure class="wp-block-image size-full"><a href="https://www.benzinga.com/pro/?utm_source=BZprocontent112724&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="628" height="490" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/27132139/Screenshot-2024-11-27-at-9.45.44-PM.png" alt="" class="wp-image-668004" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/27132139/Screenshot-2024-11-27-at-9.45.44-PM.png 628w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/27132139/Screenshot-2024-11-27-at-9.45.44-PM-300x234.png 300w" sizes="(max-width: 628px) 100vw, 628px" /></a></figure>
<a href="https://www.benzinga.com/pro/?utm_source=BZprocontent112724&amp;t=be2bearmibe3na1" target="_blank" rel="noreferrer noopener">Chart created using Benzinga Pro</a>
Technically, the stock screams &#8216;bearish&#8217; as it lingers below key moving averages, including its 20-day and 50-day simple moving averages (SMAs). Yet, with its eight-day SMA at $86.18 and 200-day SMA at $82.52, there's a faint glimmer of hope—potential buyers might find solace in its nearly oversold RSI of 38.51.
Investor sentiment remains tepid, but big names like Soros Capital Management and Bridgewater Associates are quietly building stakes. Is Alibaba the beaten-down stock that contrarians love to bet on? 
Maybe, but upcoming U.S. tariffs could spoil the progress.
Read Also: <a href="https://www.benzinga.com/24/11/42120110/alibaba-reshapes-e-commerce-operations-names-jiang-fan-as-unit-ceo">Alibaba Reshapes E-Commerce Operations, Names Jiang Fan as Unit CEO</a>
<h2 class="wp-block-heading">PDD Holdings: The High-Flyer Turned Free-Faller</h2>
PDD's stock paints a darker picture. After a blistering run with Temu's U.S. expansion, the company now faces an aggressive sell-off. 
Down 33.22% over six months and 20.52% in the past month, it seems Wall Street is questioning the sustainability of Temu's discount-driven strategy. 
<figure class="wp-block-image size-full"><a href="https://www.benzinga.com/pro/?utm_source=BZprocontent112724&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="628" height="490" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/27132201/Screenshot-2024-11-27-at-9.45.59-PM.png" alt="" class="wp-image-668005" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/27132201/Screenshot-2024-11-27-at-9.45.59-PM.png 628w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/27132201/Screenshot-2024-11-27-at-9.45.59-PM-300x234.png 300w" sizes="(max-width: 628px) 100vw, 628px" /></a></figure>
<a href="https://www.benzinga.com/pro/?utm_source=BZprocontent112724&amp;t=be2bearmibe3na1" target="_blank" rel="noreferrer noopener">Chart created using Benzinga Pro</a>
Technical indicators are grim, with the MACD at a negative 6.18 and an RSI of 28.79 signaling oversold territory.
Even institutional love, like Fisher Asset Management upping its stake, hasn't stopped analysts from jumping ship. 
JPMorgan downgraded PDD to neutral with a slashed price target of $105, while Benchmark trimmed its target to $160 from $185. 
Meanwhile, fears over regulatory risks and national security concerns tied to Temu only add to the bearish momentum.
<h2 class="wp-block-heading">The Verdict: Avoid Or Opportunistic Entry?</h2>
Both stocks are under pressure, but PDD's steeper declines and bearish outlook suggest it's in a riskier position.
Alibaba, with its diversified revenue streams and slightly less dramatic drop, might hold more appeal for the brave. 
Still, with Trump-era tariffs looming, both stocks might have more turbulence ahead. For now, it's about &#8216;who's losing less badly,&#8217; and neither is doing well.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/markets/24/11/42175308/the-fall-of-ant-groups-ipo-alibabas-missteps-legal-battles-and-a-433-5m-settlement">The Fall of Ant Group&#8217;s IPO: Alibaba&#8217;s Missteps, Legal Battles, and a $433.5M Settlement</a></li>
</ul>

Asia

Technicals

Tech

BABA

ALIBABA GROUP HOLDING LTD by Alibaba Group Holding Limited

BABAF

Citigourp Global Markets 2% Protected Notes Linked To The Djia

Alibaba Vs. PDD: A Grim Showdown In Chinese E-Commerce Stocks

Macro Economic Events

WIIM

Economics

SPDR Dow Jones Industrial Average ETF Trust

Major indexes are lower after the core PCE price index was in line with estimates. Multiple large tech stocks also dropped following quarterly earnings.

HP Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HPQ#NYSE">HPQ</a>) shares are trading lower Wednesday after the company reported its fourth-quarter financial results and issued guidance for the upcoming quarter that fell short of analyst expectations. Here&#8217;s <a href="https://www.benzinga.com/markets/24/11/42213335/hp-shares-plunge-in-wednesday-pre-market-after-weak-q4-projections">what you need to know.</a>
What To Know: HP posted adjusted earnings per share of 93 cents for the quarter, which matched the consensus estimate. Revenue came in at $14.05 billion, surpassing the $13.99 billion estimate. The company&#8217;s top-line results were up from $13.82 billion reported in the same period last year, according to <a href="https://pro.benzinga.com/dashboard">Benzinga Pro.</a>
HP noted that net cash provided by operating activities in the quarter was $1.6 billion. The company also generated $1.5 billion in free cash flow. HP ended the quarter with $7.7 billion in inventory.
In addition to the quarterly results, HP announced a 5% increase in its dividend, raising the quarterly payout from $0.2756 to $0.2894 per share. The increased dividend is payable on Jan. 2 to shareholders of record as of Dec. 11.
HP projected adjusted earnings of 70 cents to 76 cents per share for the first quarter of fiscal 2025, versus estimates of 85 cents per share. For the full fiscal year, the company forecasted earnings between $3.45 and $3.75 per share, compared to estimates of $3.60 per share.
CEO Enrique Lores highlighted revenue growth in the Personal Systems and Print divisions, expressing optimism about the company&#8217;s ability to &#8220;capitalize on the commercial opportunity and lead the future of work.&#8221; 
Analysts responded to the print by maintaining Neutral ratings and adjusting price targets:
<ul>
<li>Barclays analyst Tim Long maintained an Equal-Weight rating and raised the price target from $32 to $35.</li>
<li>TD Cowen analyst Krish Sankar maintained a Hold rating and raised the price target from $32 to $39.</li>
<li>Citigroup analyst Asiya Merchant maintained a Neutral rating and lowered the price target from $37 to $36.50.</li>
</ul>
HP Price Action: HP shares were down 12.5% at $34.17 at the time of writing, according to <a href="https://pro.benzinga.com/dashboard">Benzinga Pro.</a>
<figure class="wp-block-image size-large is-resized"><a href="https://benzinga.slack.com/archives/D072651PB4K/p1727794380964569"><img loading="lazy" decoding="async" width="1024" height="541" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/27131126/HP-1024x541.png" alt="" class="wp-image-667981" style="width:483px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/27131126/HP-1024x541.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/27131126/HP-300x159.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/27131126/HP-768x406.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/27131126/HP.png 1443w" sizes="(max-width: 1024px) 100vw, 1024px" /></a></figure>
Read Next:
<ul>
<li><a href="https://www.benzinga.com/24/11/42220837/iris-energy-arrowhead-pharmaceuticals-urban-outfitters-and-other-big-stocks-moving-higher-on-wednesday">Iris Energy, Arrowhead Pharmaceuticals, Urban Outfitters And Other Big Stocks Moving Higher On Wednesday</a></li>
</ul>
Image via Shutterstock.

Earnings

Price Target

Movers

HP Stock Is Falling Wednesday: What's Going On?

<a href="https://news.bloomberglaw.com/business-and-practice/autodesk-ceo-says-focused-on-cost-cuts-after-starboard-pressure#:~:text=Autodesk%20Inc.,activist%20investor%20Starboard%20Value%20LP%20.">https://news.bloomberglaw.com/business-and-practice/autodesk-ceo-says-focused-on-cost-cuts-after-starboard-pressure#:~:text=Autodesk%20Inc.,activist%20investor%20Starboard%20Value%20LP%20.</a>
Autodesk Inc. Chief Executive Officer Andrew Anagnost said the company is focused on cutting costs in its sales and marketing teams, a move that comes following pressure from activist investor Starboard Value LP.
"We are very much focused on sales and marketing optimization moving forward," Anagnost said Wednesday in an interview on Bloomberg Television. "That is something we and all of the investment community agree is an important target for Autodesk."
Scrutiny intensified earlier this year on the maker of engineering software after an accounting investigation delayed its financial filings and led to the replacement of its finance chief. ...
 &nbsp;

ADSK

'Autodesk CEO Says Focused On Cost Cuts After Starboard Pressure' - Bloomberg Law

Whales with a lot of money to spend have taken a noticeably bearish stance on Citigroup.
Looking at options history for Citigroup (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/C#NYSE">C</a>) we detected 15 trades.
If we consider the specifics of each trade, it is accurate to state that 40% of the investors opened trades with bullish expectations and 60% with bearish.
From the overall spotted trades, 9 are puts, for a total amount of $443,285 and 6, calls, for a total amount of $254,927.
<h3>Predicted Price Range</h3>
Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $47.5 to $77.5 for Citigroup during the past quarter. 
<h3>Volume &amp; Open Interest Development</h3>
In today's trading context, the average open interest for options of Citigroup stands at 13369.42, with a total volume reaching 47,345.00. The accompanying chart delineates the progression of both call and put option volume and open interest for high-value trades in Citigroup, situated within the strike price corridor from $47.5 to $77.5, throughout the last 30 days.
<h3>Citigroup 30-Day Option Volume &amp; Interest Snapshot</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1732734968_0.png" alt="Options Call Chart" />
<h3>Significant Options Trades Detected:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>C</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$0.31</td>
<td>$0.3</td>
<td>$0.31</td>
<td>$60.00</td>
<td>$93.0K</td>
<td>32.6K</td>
<td>4.0K</td>
</tr>
<tr>
<td>C</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>11/29/24</td>
<td>$0.35</td>
<td>$0.34</td>
<td>$0.35</td>
<td>$70.00</td>
<td>$85.9K</td>
<td>2.0K</td>
<td>4.5K</td>
</tr>
<tr>
<td>C</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>06/20/25</td>
<td>$5.8</td>
<td>$5.75</td>
<td>$5.8</td>
<td>$70.00</td>
<td>$58.0K</td>
<td>24.0K</td>
<td>104</td>
</tr>
<tr>
<td>C</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>11/29/24</td>
<td>$0.62</td>
<td>$0.59</td>
<td>$0.62</td>
<td>$70.00</td>
<td>$51.9K</td>
<td>5.3K</td>
<td>1.8K</td>
</tr>
<tr>
<td>C</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$9.8</td>
<td>$9.7</td>
<td>$9.8</td>
<td>$75.00</td>
<td>$49.0K</td>
<td>246</td>
<td>50</td>
</tr>
</tbody>
</table>

<h3>About Citigroup</h3>
Citigroup is a global financial-services company doing business in more than 100 countries and jurisdictions. Citigroup's operations are organized into five primary segments: services, markets, banking, US personal banking, and wealth management. The bank's primary services include cross-border banking needs for multinational corporates, investment banking and trading, and credit card services in the United States.
After a thorough review of the options trading surrounding Citigroup, we move to examine the company in more detail. This includes an assessment of its current market status and performance.
<h3>Current Position of Citigroup</h3>
<ul>
<li>Trading volume stands at 5,003,621, with C's price up by 0.05%, positioned at $69.78.</li>
<li>RSI indicators show the stock to be may be approaching overbought.</li>
<li>Earnings announcement expected in 49 days.</li>
</ul>
<h3>Expert Opinions on Citigroup</h3>
A total of 2 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $101.0.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; An analyst from Oppenheimer has decided to maintain their Outperform rating on Citigroup, which currently sits at a price target of $107. 
&#x2A; Maintaining their stance, an analyst from Wells Fargo continues to hold a Overweight rating for Citigroup, targeting a price of $95. 
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Citigroup options trades with real-time alerts from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.

Options

Spotlight on Citigroup: Analyzing the Surge in Options Activity

Investors with a lot of money to spend have taken a bearish stance on Applied Optoelectronics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAOI#NASDAQ">AAOI</a>).
And retail traders should know.
We noticed this today when the positions showed up on publicly available options history that we track here at Benzinga.
Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with AAOI, it often means somebody knows something is about to happen.
Today, Benzinga's options scanner spotted 13 options trades for Applied Optoelectronics.
This isn't normal.
The overall sentiment of these big-money traders is split between 7% bullish and 76%, bearish.
Out of all of the options we uncovered, there was 1 put, for a total amount of $29,800, and 12, calls, for a total amount of $854,798.
<h3>Projected Price Targets</h3>
After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $10.0 and $50.0 for Applied Optoelectronics, spanning the last three months.
<h3>Volume &amp; Open Interest Trends</h3>
Assessing the volume and open interest is a strategic step in options trading. These metrics shed light on the liquidity and investor interest in Applied Optoelectronics's options at specified strike prices. The forthcoming data visualizes the fluctuation in volume and open interest for both calls and puts, linked to Applied Optoelectronics's substantial trades, within a strike price spectrum from $10.0 to $50.0 over the preceding 30 days.
<h3>Applied Optoelectronics Option Activity Analysis: Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1732734962_0.png" alt="Options Call Chart" />
<h3>Largest Options Trades Observed:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>AAOI</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>12/20/24</td>
<td>$26.2</td>
<td>$25.3</td>
<td>$25.48</td>
<td>$10.00</td>
<td>$254.8K</td>
<td>3.7K</td>
<td align="right">0</td>
</tr>
<tr>
<td>AAOI</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>03/21/25</td>
<td>$11.0</td>
<td>$10.5</td>
<td>$10.6</td>
<td>$30.00</td>
<td>$106.0K</td>
<td>1.6K</td>
<td align="right">104</td>
</tr>
<tr>
<td>AAOI</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>12/20/24</td>
<td>$16.8</td>
<td>$16.0</td>
<td>$16.0</td>
<td>$20.00</td>
<td>$80.0K</td>
<td>2.0K</td>
<td align="right">50</td>
</tr>
<tr>
<td>AAOI</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$16.6</td>
<td>$15.3</td>
<td>$15.67</td>
<td>$35.00</td>
<td>$78.3K</td>
<td>226</td>
<td align="right">51</td>
</tr>
<tr>
<td>AAOI</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$2.4</td>
<td>$2.4</td>
<td>$2.4</td>
<td>$50.00</td>
<td>$71.5K</td>
<td>3.9K</td>
<td align="right">29</td>
</tr>
</tbody>
</table>

<h3>About Applied Optoelectronics</h3>
Applied Optoelectronics Inc is a provider of fiber-optic networking products for the Internet data center, cable television, telecommunications and fiber-to-the-home end markets. The company focuses on designing and manufacturing a range of optical communication products from components, to subassemblies, and modules to complete turn-key equipment. Demand for Applied Optoelectronics is driven by bandwidth demand in end markets. Through direct sales personnel, and manufacturing teams in the United States, China, and Taiwan, the company coordinates with customers to determine product design, qualifications, and performance. The company derives maximum revenue from Taiwan.
In light of the recent options history for Applied Optoelectronics, it's now appropriate to focus on the company itself. We aim to explore its current performance.
<h3>Present Market Standing of Applied Optoelectronics</h3>
<ul>
<li>Currently trading with a volume of 2,174,375, the AAOI's price is up by 0.84%, now at $37.33. </li>
<li>RSI readings suggest the stock is currently may be overbought.</li>
<li>Anticipated earnings release is in 85 days.</li>
</ul>
<h3>Professional Analyst Ratings for Applied Optoelectronics</h3>
In the last month, 3 experts released ratings on this stock with an average target price of $25.166666666666668.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; An analyst from Northland Capital Markets persists with their Outperform rating on Applied Optoelectronics, maintaining a target price of $25. 
&#x2A; Consistent in their evaluation, an analyst from Raymond James keeps a Outperform rating on Applied Optoelectronics with a target price of $23. 
&#x2A; Consistent in their evaluation, an analyst from Rosenblatt keeps a Buy rating on Applied Optoelectronics with a target price of $27. 
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Applied Optoelectronics with <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> for real-time alerts.

AAOI

Market Whales and Their Recent Bets on AAOI Options

High-rolling investors have positioned themselves bullish on PepsiCo (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PEP#NASDAQ">PEP</a>), and it's important for retail traders to take note. 
\This activity came to our attention today through Benzinga's tracking of publicly available options data. The identities of these investors are uncertain, but such a significant move in PEP often signals that someone has privileged information.
Today, Benzinga's options scanner spotted 8 options trades for PepsiCo. This is not a typical pattern.
The sentiment among these major traders is split, with 50% bullish and 50% bearish. Among all the options we identified, there was one put, amounting to $38,850, and 7 calls, totaling $446,181.
<h3>Predicted Price Range</h3>
Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $150.0 to $165.0 for PepsiCo over the last 3 months. 
<h3>Analyzing Volume &amp; Open Interest</h3>
Examining the volume and open interest provides crucial insights into stock research. This information is key in gauging liquidity and interest levels for PepsiCo's options at certain strike prices. Below, we present a snapshot of the trends in volume and open interest for calls and puts across PepsiCo's significant trades, within a strike price range of $150.0 to $165.0, over the past month.
<h3>PepsiCo Call and Put Volume: 30-Day Overview</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1732734957_0.png" alt="Options Call Chart" />
<h3>Significant Options Trades Detected:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>PEP</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>12/20/24</td>
<td>$2.15</td>
<td>$2.1</td>
<td>$2.15</td>
<td>$165.00</td>
<td>$146.6K</td>
<td>5.0K</td>
<td>1.7K</td>
</tr>
<tr>
<td>PEP</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/15/27</td>
<td>$27.3</td>
<td>$26.4</td>
<td>$26.4</td>
<td>$150.00</td>
<td>$71.2K</td>
<td>21</td>
<td>27</td>
</tr>
<tr>
<td>PEP</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>12/20/24</td>
<td>$1.5</td>
<td>$1.49</td>
<td>$1.5</td>
<td>$165.00</td>
<td>$60.3K</td>
<td>5.0K</td>
<td>477</td>
</tr>
<tr>
<td>PEP</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>12/20/24</td>
<td>$2.2</td>
<td>$2.15</td>
<td>$2.15</td>
<td>$165.00</td>
<td>$59.7K</td>
<td>5.0K</td>
<td>1.9K</td>
</tr>
<tr>
<td>PEP</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>12/20/24</td>
<td>$1.62</td>
<td>$1.5</td>
<td>$1.5</td>
<td>$165.00</td>
<td>$40.8K</td>
<td>5.0K</td>
<td>753</td>
</tr>
</tbody>
</table>

<h3>About PepsiCo</h3>
PepsiCo is a global leader in snacks and beverages, owning well-known household brands including Pepsi, Mountain Dew, Gatorade, Lay's, Cheetos, and Doritos, among others. The company dominates the global savory snacks market and also ranks as the second-largest beverage provider in the world (behind Coca-Cola) with diversified exposure to carbonated soft drinks, or CSD, as well as water, sports, and energy drink offerings. Convenience foods account for approximately 55% of its total revenue, with beverages making up the rest. Pepsi owns the bulk of its manufacturing and distribution capacity in the US and overseas. International markets make up 40% of total sales and one third of operating profits.
After a thorough review of the options trading surrounding PepsiCo, we move to examine the company in more detail. This includes an assessment of its current market status and performance.
<h3>Current Position of PepsiCo</h3>
<ul>
<li>Trading volume stands at 1,819,910, with PEP's price up by 0.39%, positioned at $162.8.</li>
<li>RSI indicators show the stock to be is currently neutral between overbought and oversold.</li>
<li>Earnings announcement expected in 72 days.</li>
</ul>
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights">Click here for access</a>.
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for PepsiCo with <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> for real-time alerts.

Market Whales and Their Recent Bets on PEP Options

<a href="https://www.bloomberg.com/news/articles/2024-11-27/uber-faces-ftc-consumer-protection-probe-over-subscription-plans">https://www.bloomberg.com/news/articles/2024-11-27/uber-faces-ftc-consumer-protection-probe-over-subscription-plans</a>
&nbsp;
The US <a href="https://www.bloomberg.com/quote/13362Z:US">Federal Trade Commission</a> is looking into whether <a href="https://www.bloomberg.com/quote/UBER:US">Uber Technologies Inc.</a> violated consumer protection laws with its flagship subscription service.
The FTC is investigating Uber after customers complained the company signed them up for the Uber One subscription product without their consent and made it difficult to cancel, according to documents viewed by Bloomberg. The investigation was opened earlier this year.

UBER

'Uber Faces FTC Consumer Protection Probe Over Subscriptions; Agency Opened Investigation Earlier This Year Amid Complaints; Uber's Lawyers Complained To FTC About Rushed Settlement' - Bloomberg News

President-elect Donald Trump has nominated Dr. Jay Bhattacharya, a Stanford physician and economist known for his critiques of pandemic lockdowns and vaccine mandates, to serve as director of the <a target="_blank" href="https://www.benzinga.com/24/11/42013119/whats-going-on-with-large-european-and-us-vaccine-makers" rel="noreferrer noopener">National Institutes of Health (NIH)</a>.
Bhattacharya gained prominence as a co-author of the Great Barrington Declaration, a controversial 2020 manifesto that opposed widespread lockdowns, advocating instead for "focused protection" of vulnerable populations while allowing the virus to spread among lower-risk groups to achieve herd immunity.
Also Read: <a target="_blank" href="https://www.benzinga.com/government/regulations/24/11/41866438/donald-trumps-second-term-could-reshape-us-healthcare-system-with-major-impacts-on-affordable-care-act-and-medicare" rel="noreferrer noopener">Donald Trump&#8217;s Second Term Could Reshape US Healthcare System, With Major Impacts on Affordable Care Act And Medicare</a>
The declaration, widely criticized by mainstream scientists and public health officials, framed Bhattacharya as a divisive figure in public health debates.
If confirmed by the Senate, Bhattacharya will oversee the NIH's $48 billion budget and 27 institutes, which fund critical research on diseases like cancer and diabetes, the New York Times <a href="https://www.nytimes.com/2024/11/26/us/politics/jay-bhattacharya-nih-trump.html" target="_blank" rel="noreferrer noopener">writes</a>. He has called for significant reforms to the NIH, arguing that the agency suffers from "groupthink" and overreach by entrenched civil servants, an NPR <a href="https://www.npr.org/sections/shots-health-news/2024/11/26/nx-s1-5195168/nih-bhattacharya-trump-election-2024" target="_blank" rel="noreferrer noopener">report</a> adds.
"Together, Jay and RFK Jr. will restore the NIH to a Gold Standard of Medical Research as they examine the underlying causes of, and solutions to, America's biggest health challenges, including our Crisis of Chronic Illness and Disease," Trump <a href="https://truthsocial.com/@realDonaldTrump/113552352326424231">wrote </a>in a Truth Social post.
However, critics worry his leadership could undermine public trust in science, given his past positions on COVID-19 policies. Dr. Francis Collins, former NIH director, previously dismissed Bhattacharya's views as "fringe." However, he has acknowledged that pandemic strategies may have over-prioritized public health goals at the expense of economic <a target="_blank" href="https://www.benzinga.com/government/regulations/24/11/41936736/fda-commissioner-califf-candid-on-trumps-impact-we-just-dont-know-whats-going-to-happen" rel="noreferrer noopener">and social considerations</a>.
Bhattacharya's partnership with Robert F. Kennedy Jr., Trump's pick to lead the Department of Health and Human Services, has further fueled concerns. Kennedy's history of promoting unscientific theories about vaccines and other health measures raises questions about how NIH research priorities might shift under their leadership.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/11/42016909/trumps-win-economic-challenges-lead-to-tougher-outlook-for-renewable-energy-stocks-morgan-stanley" target="_blank" rel="noreferrer noopener">Trump&#8217;s Win, Economic Challenges Lead to Tougher Outlook for Renewable Energy Stocks: Morgan Stanley</a></li>
</ul>
Photo: Shutterstock

Biotech

Government

Politics

General

Trump Taps Pandemic Lockdown Critic Jay Bhattacharya To Overhaul NIH

CrowdStrike Holdings Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRWD#NASDAQ">CRWD</a>) shares are falling Wednesday following the release of the company&#8217;s <a href="https://www.benzinga.com/news/earnings/24/11/42202105/crowdstrike-beats-q3-earnings-revenue-estimates-cybersecurity-company-highlights-incredible-success-retaining-customers-following-it-outage">third-quarter financial results</a> and analyst changes. 
What To Know: CrowdStrike reported third-quarter revenue of $1.01 billion, beating the consensus estimate of $982.36 million and reflecting a 29% year-over-year increase. Adjusted earnings per share came in at 93 cents, beating the estimate of 81 cents. 
The company's annual recurring revenue grew 27% year-over-year to $4.02 billion, with $153 million added in net new ARR during the quarter.
Outlook: CrowdStrike issued guidance for the fourth quarter, projecting revenue between $1.029 billion and $1.035 billion, roughly in line with the consensus estimate of $1.03 billion. Adjusted earnings per share are expected to be between 84 cents and 86 cents, matching the 86 cents consensus estimate. 
Guidance was roughly in-line with consensus estimates. For fiscal year 2025, CrowdStrike sees revenue in the range of $3.923 billion to $3.931 billion, slightly above estimates of $3.897 billion and sees adjusted EPS guidance to $3.74 to $3.76, above the $3.63 consensus.
CEO George Kurtz emphasized the company's customer retention rate of over 97% and highlighted CrowdStrike's success in expanding relationships with clients impacted by a global IT outage earlier in the year.
Analyst Reactions:
HSBC downgraded the stock from Buy to Hold and set a price target of $347 following the report. Other <a href="https://www.benzinga.com/24/11/42220386/crowdstrike-sees-strong-module-adoption-valuation-concerns-persist-analysts">analysts reactions to the report</a> are as follows:
<ul>
<li>Needham: Maintained Buy rating and raised price target from $360 to $420.</li>
<li>Rosenblatt: Maintained Buy rating with a price target of $385.</li>
<li>Baird: Maintained Outperform rating and raised price target from $375 to $390.</li>
<li>WestPark Capital: Reiterated Hold rating.</li>
<li>B of A Securities: Maintained Buy rating and raised price target from $365 to $400.</li>
<li>Susquehanna: Maintained Positive rating and raised price target from $310 to $400.</li>
<li>BMO Capital: Maintained Outperform rating and raised price target from $315 to $380.</li>
<li>Citigroup: Maintained Buy rating and raised price target from $300 to $400.</li>
<li>Oppenheimer: Maintained Outperform rating and raised price target from $365 to $410.</li>
<li>Piper Sandler: Maintained Overweight rating and raised price target from $290 to $375.</li>
<li>RBC Capital: Maintained Outperform rating and lowered price target from $370 to $365.</li>
<li>Wells Fargo: Maintained Overweight rating and raised price target from $350 to $400.</li>
</ul>
CRWD Price Action: CrowdStrike shares were down 6.18% at $341.80 at the time of writing, according to<a href="https://pro.benzinga.com/dashboard"> Benzinga Pro.</a>
<figure class="wp-block-image size-large is-resized"><a href="https://benzinga.slack.com/archives/D072651PB4K/p1727794380964569"><img loading="lazy" decoding="async" width="1024" height="534" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/27134042/CRWD-1024x534.png" alt="" class="wp-image-668035" style="width:499px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/27134042/CRWD-1024x534.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/27134042/CRWD-300x157.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/27134042/CRWD-768x401.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/27134042/CRWD.png 1474w" sizes="(max-width: 1024px) 100vw, 1024px" /></a></figure>
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/global/24/11/42220682/trump-tariffs-on-mexico-could-affect-beer-why-your-modelo-corona-could-cost-more-next-year">Trump Tariffs On Mexico Could Affect Beer: Why Your Modelo, Corona Could Cost More Next Year</a></li>
</ul>
Image Via Shutterstock.

CRWD

CrowdStrike Shares Are Trading Lower Wednesday: What's Going On?

Ubisoft Montreal is reportedly developing a social simulation game codenamed Alterra, blending elements inspired by Nintendo ADR&#8216;s (OTC:<a class="ticker" href="https://www.benzinga.com/stock/NTDOY#OTC">NTDOY</a>) Animal Crossing and Microsoft Corp.&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>) <a href="https://www.benzinga.com/general/gaming">Minecraft. </a>
The project, led by former Gotham Knights creative director Patrick Redding has been in development for approximately 18 months, according to a <a href="https://insider-gaming.com/ubisoft-alterra-animal-crossing-inspired-game/">report</a> from Insider Gaming.
<h1 class="wp-block-heading">A New Direction: Social Sims And Voxel Creativity</h1>
Alterra is said to have emerged from the remnants of a canceled Ubisoft Montreal project, which also centered around voxel-based creation. 
See Also: <a href="https://www.benzinga.com/24/11/42219464/shuhei-yoshida-to-leave-playstation-after-30-years-id-like-to-stay-in-the-industry-xboxs-phil-spencer-reacts">Shuhei Yoshida To Leave PlayStation After 30 Years: &#8216;I&#8217;d Like To Stay In The Industry&#8217;; Xbox&#8217;s Phil Spencer Reacts</a>
The new game is described as an "Animal Crossing-inspired social sim," where players inhabit a home island shared with NPCs known as Matterlings. These quirky characters are likened to Funko Pop figures, featuring exaggerated head proportions and designs that blend fictional and real-world creatures, ranging from polar bears to dragons.
The gameplay reportedly combines social elements with a voxel-based building mechanic reminiscent of <a href="https://www.benzinga.com/general/gaming/24/09/40990487/minecraft-players-bring-new-york-city-to-life-check-out-stunning-images-of-digital-replica">Minecraft.</a> Players gather resources from different biomes beyond their home island to craft items and structures. Each biome features unique Matterlings, enemies and materials.
For example, an ice biome might host snow-themed Matterlings and provide resources for crafting objects made of snow and ice. Players may also encounter others while exploring these diverse regions.
<h1 class="wp-block-heading">Key Talent And Timeline</h1>
The project is helmed by Ubisoft Entertainment SA&#8216;s (OTC:<a class="ticker" href="https://www.benzinga.com/stock/UBSFF#OTC">UBSFF</a>) veteran Fabien Lhéraud, serving as lead producer, alongside Redding's creative leadership.
While details remain limited, Insider Gaming's report suggests that Alterra is still in its early stages, with a release likely several years away.
<h1 class="wp-block-heading">The Broader Ubisoft Landscape</h1>
The publisher is gearing up for the release of Assassin's Creed Shadows and Anno 117: Pax Romana next year. Meanwhile, projects like Beyond Good &amp; Evil 2 and the <a href="https://www.benzinga.com/general/gaming/24/10/41554263/ubisoft-strategy-to-blame-for-prince-of-persias-poor-sales-baldurs-gate-3-exec-thinks-so">Prince of Persia</a>: Sands of Time remake continue to face protracted development timelines, with the latter now eyeing a 2026 release.
In addition, Ubisoft recently ventured into blockchain gaming, launching its first NFT-based game featuring collectible figurines <a href="https://www.benzinga.com/markets/cryptocurrency/24/10/41632648/ubisoft-launches-blockchain-game-with-nfts-priced-as-high-as-64-000">priced as high as $64,000.</a>
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/gaming/24/11/42199470/project-polaris-hits-full-scale-production-whats-next-for-the-witcher-and-cd-projekt">Project Polaris Hits Full-Scale Production: What&#8217;s Next For The Witcher And CD Projekt?</a></li>
</ul>

Gaming

MSFT

NTDOY

UBSFF

Animal Crossing Meets Minecraft In Ubisoft's Upcoming Game: Report

During the last three months, 4 analysts shared their evaluations of Frontline (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FRO#NYSE">FRO</a>), revealing diverse outlooks from bullish to bearish.
The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $28.0, along with a high estimate of $30.00 and a low estimate of $26.00. A decline of 2.34% from the prior average price target is evident in the current average. 
<img src="https://www.benzinga.com/files/images/story/2024/1732734149_0.png" alt="price target chart" />
<h2>Interpreting Analyst Ratings: A Closer Look</h2>
The analysis of recent analyst actions sheds light on the perception of Frontline by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Omar Nokta</td>
<td>Jefferies</td>
<td>Maintains</td>
<td>Buy</td>
<td>$26.00</td>
<td>$26.00</td>
</tr>
<tr>
<td>Omar Nokta</td>
<td>Jefferies</td>
<td>Lowers</td>
<td>Buy</td>
<td>$26.00</td>
<td>$30.00</td>
</tr>
<tr>
<td>Gregory Lewis</td>
<td>BTIG</td>
<td>Announces</td>
<td>Buy</td>
<td>$30.00</td>
<td>-</td>
</tr>
<tr>
<td>Omar Nokta</td>
<td>Jefferies</td>
<td>Maintains</td>
<td>Buy</td>
<td>$30.00</td>
<td>$30.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Frontline. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of Frontline compared to the broader market.</li>
<li>Price Targets: Analysts gauge the dynamics of price targets, providing estimates for the future value of Frontline's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Frontline's market standing. Stay informed and make well-considered decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/FRO/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Frontline analyst ratings.</a>
<h2>About Frontline</h2>
Frontline PLC is an international shipping company engaged in the seaborne transportation of crude oil and oil products. Group operates through the tankers segment. The tankers segment includes crude oil tankers and product tankers. Its geographical area of operation includes Arabian Gulf, West African, the North Sea, and the Caribbean. Frontline earns revenue through voyage charters, time charters, and a finance lease. It is also involved in the charter, purchase, and sale of vessels.
<h3>Key Indicators: Frontline's Financial Health</h3>
Market Capitalization Analysis: Falling below industry benchmarks, the company's market capitalization reflects a reduced size compared to peers. This positioning may be influenced by factors such as growth expectations or operational capacity.
Revenue Growth: Frontline's remarkable performance in 3 months is evident. As of 30 June, 2024, the company achieved an impressive revenue growth rate of 8.44%. This signifies a substantial increase in the company's top-line earnings. When compared to others in the Energy sector, the company excelled with a growth rate higher than the average among peers.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of 33.73%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): Frontline's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 7.81% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of 2.87%, the company showcases effective utilization of assets.
Debt Management: Frontline's debt-to-equity ratio is below the industry average. With a ratio of 1.59, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
<h2>Analyst Ratings: What Are They?</h2>
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Expectations For Frontline's Future

During the last three months, 4 analysts shared their evaluations of Adaptimmune Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADAP#NASDAQ">ADAP</a>), revealing diverse outlooks from bullish to bearish.
The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $2.88, along with a high estimate of $3.50 and a low estimate of $1.50. Observing a downward trend, the current average is 20.44% lower than the prior average price target of $3.62. 
<img src="https://www.benzinga.com/files/images/story/2024/1732734103_0.png" alt="price target chart" />
<h2>Understanding Analyst Ratings: A Comprehensive Breakdown</h2>
The standing of Adaptimmune Therapeutics among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Graig Suvannavejh</td>
<td>Mizuho</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$1.50</td>
<td>$3.00</td>
</tr>
<tr>
<td>Arthur He</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$3.50</td>
<td>$3.50</td>
</tr>
<tr>
<td>Michael Schmidt</td>
<td>Guggenheim</td>
<td>Lowers</td>
<td>Buy</td>
<td>$3.00</td>
<td>$4.00</td>
</tr>
<tr>
<td>Arthur He</td>
<td>HC Wainwright &amp; Co.</td>
<td>Lowers</td>
<td>Buy</td>
<td>$3.50</td>
<td>$4.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Adaptimmune Therapeutics. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of Adaptimmune Therapeutics compared to the broader market.</li>
<li>Price Targets: Analysts explore the dynamics of price targets, providing estimates for the future value of Adaptimmune Therapeutics's stock. This examination reveals shifts in analysts' expectations over time.</li>
</ul>
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Adaptimmune Therapeutics's market standing. Stay informed and make data-driven decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/ADAP/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Adaptimmune Therapeutics analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.
<h2>All You Need to Know About Adaptimmune Therapeutics</h2>
Adaptimmune Therapeutics PLC is a clinical-stage biopharmaceutical company. It focused on providing novel cell therapies to patients, particularly in solid tumors. It has developed a comprehensive proprietary platform that enables it to identify cancer targets, find and genetically engineer T-cell receptors, and produce TCR therapeutic candidates for administration to patients. Its programs include MAGE-A4 SPEAR T-cell therapy, NY-ESO SPEAR T-cell, CD70 and others for multiple cancer types.
<h3>Financial Milestones: Adaptimmune Therapeutics's Journey</h3>
Market Capitalization Analysis: Reflecting a smaller scale, the company's market capitalization is positioned below industry averages. This could be attributed to factors such as growth expectations or operational capacity.
Revenue Growth: Adaptimmune Therapeutics's remarkable performance in 3 months is evident. As of 30 September, 2024, the company achieved an impressive revenue growth rate of 458.83%. This signifies a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Health Care sector.
Net Margin: Adaptimmune Therapeutics's net margin is impressive, surpassing industry averages. With a net margin of -43.07%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): Adaptimmune Therapeutics's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of -19.99%, the company may face hurdles in achieving optimal financial performance.
Return on Assets (ROA): Adaptimmune Therapeutics's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of -5.51%, the company may face hurdles in achieving optimal financial returns.
Debt Management: With a high debt-to-equity ratio of 0.93, Adaptimmune Therapeutics faces challenges in effectively managing its debt levels, indicating potential financial strain.
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ADAP

Demystifying Adaptimmune Therapeutics: Insights From 4 Analyst Reviews

Analysts' ratings for Regency Centers (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REG#NASDAQ">REG</a>) over the last quarter vary from bullish to bearish, as provided by 6 analysts.
The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">2</td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $78.67, with a high estimate of $80.00 and a low estimate of $75.00. This upward trend is apparent, with the current average reflecting a 7.77% increase from the previous average price target of $73.00.
<img src="https://www.benzinga.com/files/images/story/2024/1732734092_0.png" alt="price target chart" />
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
The analysis of recent analyst actions sheds light on the perception of Regency Centers by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Michael Gorman</td>
<td>BTIG</td>
<td>Raises</td>
<td>Buy</td>
<td>$79.00</td>
<td>$72.00</td>
</tr>
<tr>
<td>Michael Mueller</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$80.00</td>
<td>$77.00</td>
</tr>
<tr>
<td>Wesley Golladay</td>
<td>Baird</td>
<td>Raises</td>
<td>Outperform</td>
<td>$78.00</td>
<td>$71.00</td>
</tr>
<tr>
<td>Todd Thomas</td>
<td>Keybanc</td>
<td>Announces</td>
<td>Overweight</td>
<td>$80.00</td>
<td>-</td>
</tr>
<tr>
<td>Derek Johnston</td>
<td>Deutsche Bank</td>
<td>Raises</td>
<td>Hold</td>
<td>$75.00</td>
<td>$70.00</td>
</tr>
<tr>
<td>Floris Van Dijkum</td>
<td>Compass Point</td>
<td>Raises</td>
<td>Buy</td>
<td>$80.00</td>
<td>$75.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Regency Centers. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Regency Centers compared to the broader market.</li>
<li>Price Targets: Analysts explore the dynamics of price targets, providing estimates for the future value of Regency Centers's stock. This examination reveals shifts in analysts' expectations over time.</li>
</ul>
Capture valuable insights into Regency Centers's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/REG/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Regency Centers analyst ratings.</a>
<h2>Discovering Regency Centers: A Closer Look</h2>
Regency Centers is one of the largest shopping center-focused retail REITs. The company's portfolio includes an interest in 483 properties, which includes over 57 million square feet of retail space following the completion of the Urstadt Biddle acquisition in August 2023. The portfolio is geographically diversified with 22 regional offices and no single market representing more than 12% of total company net operating income. Regency's retail portfolio is primarily composed of grocery-anchored centers, with 80% of properties featuring a grocery anchor and grocery stores representing 20% of annual base rent.
<h3>Regency Centers's Economic Impact: An Analysis</h3>
Market Capitalization Analysis: The company's market capitalization surpasses industry averages, showcasing a dominant size relative to peers and suggesting a strong market position.
Positive Revenue Trend: Examining Regency Centers's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 8.96% as of 30 September, 2024, showcasing a substantial increase in top-line earnings. When compared to others in the Real Estate sector, the company excelled with a growth rate higher than the average among peers.
Net Margin: Regency Centers's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of 27.22%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): Regency Centers's ROE is below industry standards, pointing towards difficulties in efficiently utilizing equity capital. With an ROE of 1.5%, the company may encounter challenges in delivering satisfactory returns for shareholders.
Return on Assets (ROA): Regency Centers's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of 0.79%, the company showcases efficient use of assets and strong financial health.
Debt Management: Regency Centers's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.77.
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Key Takeaways From Regency Centers Analyst Ratings

In the preceding three months, 8 analysts have released ratings for MetLife (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MET#NYSE">MET</a>), presenting a wide array of perspectives from bullish to bearish.
The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">3</td>
<td align="right">5</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $93.62, a high estimate of $99.00, and a low estimate of $90.00. Observing a 4.02% increase, the current average has risen from the previous average price target of $90.00. 
<img src="https://www.benzinga.com/files/images/story/2024/1732734080_0.png" alt="price target chart" />
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
The standing of MetLife among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Daniel Bergman</td>
<td>TD Cowen</td>
<td>Raises</td>
<td>Buy</td>
<td>$99.00</td>
<td>$97.00</td>
</tr>
<tr>
<td>Elyse Greenspan</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$93.00</td>
<td>$92.00</td>
</tr>
<tr>
<td>Alex Scott</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$90.00</td>
<td>$91.00</td>
</tr>
<tr>
<td>Elyse Greenspan</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$92.00</td>
<td>$86.00</td>
</tr>
<tr>
<td>Daniel Bergman</td>
<td>TD Cowen</td>
<td>Announces</td>
<td>Buy</td>
<td>$97.00</td>
<td>-</td>
</tr>
<tr>
<td>John Barnidge</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$92.00</td>
<td>$85.00</td>
</tr>
<tr>
<td>Suneet Kamath</td>
<td>Jefferies</td>
<td>Raises</td>
<td>Buy</td>
<td>$95.00</td>
<td>$89.00</td>
</tr>
<tr>
<td>Alex Scott</td>
<td>Barclays</td>
<td>Announces</td>
<td>Overweight</td>
<td>$91.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to MetLife. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of MetLife compared to the broader market.</li>
<li>Price Targets: Delving into movements, analysts provide estimates for the future value of MetLife's stock. This analysis reveals shifts in analysts' expectations over time.</li>
</ul>
To gain a panoramic view of MetLife's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/MET/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on MetLife analyst ratings.</a>
<h2>All You Need to Know About MetLife</h2>
MetLife is one of the largest life insurers in the us by assets and provides a variety of insurance and financial-services products. It is organized into five segments: us, Asia, Latin America, Europe/Middle East/Africa, and MetLife Holdings. The us business contributes around 50% of earnings and is broken into the group benefits segment and the retirement solutions segment. The Asia segment contributes around 22% of earnings and is mainly composed of the Japan business, with increasing contributions from India, China, and Bangladesh. The company also holds leading market positions in Mexico and Chile, with the Latin America segment contributing around 13% of earnings. The EMEA and MetLife Holdings segments contribute around 4% and 11% of earnings, respectively.
<h3>Understanding the Numbers: MetLife's Finances</h3>
Market Capitalization Analysis: The company's market capitalization is above the industry average, indicating that it is relatively larger in size compared to peers. This may suggest a higher level of investor confidence and market recognition.
Revenue Growth: MetLife's revenue growth over a period of 3 months has been noteworthy. As of 30 September, 2024, the company achieved a revenue growth rate of approximately 16.6%. This indicates a substantial increase in the company's top-line earnings. When compared to others in the Financials sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of 6.98%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): MetLife's ROE excels beyond industry benchmarks, reaching 4.39%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): MetLife's ROA excels beyond industry benchmarks, reaching 0.18%. This signifies efficient management of assets and strong financial health.
Debt Management: The company faces challenges in debt management with a debt-to-equity ratio higher than the industry average. With a ratio of 0.61, caution is advised due to increased financial risk.
<h2>The Significance of Analyst Ratings Explained</h2>
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Comments

GlobalData

News

Latest news for GlobalData (OTC:GLDAF) Stock

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga